(NEW YORK) – CBD sector gets upgrade as Mitch McConnell pushes FDA to establish regulatory rules for CBD products, which could provide the catalyst for major short-covering events in an already oversold sector.
In September, Senate Majority Leader Mitch McConnell (R-KY) inserted language into congressional spending report that called on the Food and Drug Administration (FDA) to clear a path for the lawful marketing of CBD products. Marketing for such products may involve using marijuana seo strategies to get a business’s website to appear higher in Google search rankings for better discovery by potential customers.
The FDA has said that allowing CBD to be sold as food items or dietary supplements would require it to develop alternative regulations that could take years to complete without congressional action, and this has taken a toll on the entire CBD sector over the past several months.
But McConnell, who was the chief proponent of a hemp legalization provision of the 2018 Farm Bill, isn’t interested in waiting around. Senator McConnell is asking FDA to “issue a policy of enforcement discretion with regard to certain products containing CBD” before the end of the year.
Another group of senators is also calling on the FDA to expediently implement regulations for CBD in order to protect consumers and free up the industry.
At a press conference on Tuesday, Sen. Richard Blumenthal (D-CT) said he is urging FDA to issue guidance so that CBD products can be lawfully marketed. He and five of his colleagues also sent a letter to FDA expressing their desire to speed up the rulemaking process.
With all this pressure from Congress there can be no doubt we could see some positive framework released before the end of the year, which could send the entire CBD and cannabis sector rallying.
Do you work for, or own a cannabis-related business? If so, and you need help building, setting up, or scaling your cannabis business, then you might want to consider reaching out to a cannabis consultant for advice from a marijuana industry expert.
Sector Highly Oversold
If you take a look at ETFMG Alternative Harvest (NYSE: MJ), which is an ETF that tracks the cannabis and CBD stocks, you can see the sector has been taking a beating since mid-summer as fear of FDA crackdown started to build.
But maybe things are oversold now and due for a major bounce.
The RSI on MJ is trading well below 30, which indicates this sector may be highly oversold at these levels. The MACD indicator also seems to be trading flat, which may indicate a bottom is starting to form in MJ just below $20 mark.
Could MJ and cannabis sector continue down further? Sure, absolutely! But as a whole everyone who wanted out of this sector has all but sold out by now, and this usually indicates a great buy signal for contrarian traders who like to buy into downside fear.
Compared to where it was during its high flying days in 2017 and 2018 this sector looks highly oversold, but this could also signal this sector is due for a major bounce.
CBD Sector Gets Upgraded
To this point, Ludlow Research issued note to its subscribers that some CBD stocks were down nearly 50-70% from their recent highs, and any bullish change to regulatory environment could trigger short covering within the sector as a whole.
The research firm stated, “Not all CBD companies may be able to comply and survive these new regulatory changes coming, but the ones who can now offer real big upside potential after months-long correction within the sector”
View sector upgrade alert here https://ludlowresearch.com/reports
Play on New FDA Rules
MetWood (OTC:MTWD) is a recent merger that brings public a health supplement manufacturer with FDA register production facilities. MTWD provides companies FDA registered production and labeling solutions for healthcare and consumer supplement products. The services MTWD offers could be some of the exact requirements the FDA may ask of CBD companies, thus making MTWD a unique play to win on pending FDA regulations for CBD sector.
ChineseInvestors (OTC:CIIX) produces a line a CBD based cosmetics, which is all but exempt from FDA pressure. The company revenues continue to rise, and with their focus remaining on CBD cosmetics this play could be worth a pop down in the $0.30 range.
CBD Stocks Placed on Watch
CVSI CV Sciences
KGKG Kona Gold Solutions
NBEV New Age Beverages
HIPH American Premium Water
MCOA Marijuana Company of America
BKIT Biohemp International
RMHB Rocky Mountain High Brands
RLBD Real Brands
Would you like to get an update and personal outlook on some specific stocks within this sector? Register to our free investor mailing list and tell us which stocks you have specific interest https://wallstreetnewscast.com/investors/
This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions, and recommendations of individuals and organizations deemed of interest. Wall Street Newscast (“WSNC”) does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. In Compliance with SEC Rule 17B WSNCwas compensated two thousand five hundred dollars for ongoing media services for Link Reservation and American Premium Water, each, and may hold business relationships with companies mentioned through its parent company, and thus should be considered a conflict of interest when reviewing this information. WSNC, or its affiliates, may hold a position in above securities from time to time, and thus should be considered a possible conflict of interest when reviewing this report and information. As of the date of this alert, WSNC, or any of its affiliates, held no positions in securities mentioned above. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial adviser before any and all investments.
Safe Harbor Statements:
This website includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
Small and Micro cap, or ‘penny stocks’, involve a high degree of risk, and we highly encourage investors to consult with a financial adviser before making any and all investment decisions when investing in these type of securities
- Dynavax (DVAX) Receives $27M Vaccine Purchase Order from CDC - July 1, 2020
- As COVID-19 Cases Spike Look to PPE Stocks: $LAKE $APT $GTXO - June 15, 2020
- Spike in COVID Cases May Spell Risk Off for Overvalued Stocks and Markets - June 7, 2020
- Riot Blockchain (RIOT) a Hedge on Inflation as Bitcoin Rallies - May 13, 2020
- Stock Valuations Could Set Stage for Potential Bubble Burst - May 9, 2020
- Centennial Resource (CDEV) Boosts Liquidity $468M as WTI Crude Breaks Above $20 Barrel - May 4, 2020
- Companies Should Prepare IT Spending to Thrive in New Normal - April 16, 2020
- Great Elm Capital (GEC) Provides Ventilators and Respiratory Care Equipment - April 15, 2020
- FujiFilm (FUJIY) to Ramp Up Production of Avigan for Treatment of COVID19 - April 15, 2020
- GTX Corp (GTXO) Begins Selling KN95 Face Masks for Coronavirus Outbreak - April 8, 2020